A composition for treating depression and use thereof

Abstract

The application discloses a composition for treating depression and application thereof, and the composition for treating depression comprises the following components in parts by weight: ligustilide 35-40 parts, arturn 0.5-1.5 parts and alpha-cyperone 0.1-1 part; the application firstly compounding active ingredients in Yujia pills which target 5-HT1AR and 5-HTT, and preparing a new traditional Chinese medicine efficacy component composition; in addition, the anti-depression efficacy of the active ingredients is evaluated by establishing a reserpine mouse depression model, and it is shown that the active ingredient composition screened from the 5-HT1AR and 5-HTT targets can regulate the content of monamine neurotransmitters in brain tissues to exert the anti-depression efficacy, and the in-vivo pharmacological experiment fully proves the anti-depression efficacy of the composition.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for treating depression and its application. Background Technology

[0002] Depression is a central nervous system disorder characterized by mood regulation disturbances. In recent years, the global number of people suffering from depression has exceeded 350 million, with a lifetime prevalence of 3.4%. According to the World Health Organization, depression is projected to become the second leading cause of disease worldwide by 2030. The onset of depression is influenced not only by biological and physiological factors but also by social and environmental factors. It can occur simultaneously with other diseases, and has a high risk of relapse and suicide. Furthermore, depression is increasingly affecting younger people, with a growing number of adolescents suffering from the condition, seriously endangering people's physical and mental health. Currently, treatment for depression still relies on traditional antidepressants such as reuptake inhibitors and monoamine oxidase inhibitors. While these drugs can provide some relief from depressive symptoms, only one-third of patients experience significant improvement, and the latency period for these drugs can last for weeks or even months, with severe withdrawal effects. Therefore, the development of more effective drugs for treating depression is urgently needed.

[0003] The etiology and pathogenesis of depression are complex. Currently, the main hypotheses include the monoamine neurotransmitter hypothesis, the inflammatory cytokine hypothesis, the hypothalamic-pituitary-adrenal (HPA) axis hypothesis, and the brain-derived neurotrophic factor (BDNF) hypothesis, but these remain insufficiently clear. The disease currently lacks effective treatments and has a long course; most patients require long-term or even lifelong treatment after diagnosis, placing a severe mental and economic burden on patients and their families. In recent years, with the deepening of research on depression, four classes of target-specific antidepressants have been developed: monoamine oxidase inhibitors (MAOIs), tricyclic and tetracyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNaRIs). These drugs have a certain effect on controlling the progression of depression; however, long-term use has significant side effects, easily leading to drug dependence, and patients are prone to withdrawal symptoms and relapses after discontinuation.

[0004] In traditional Chinese medicine theory, depression belongs to "depressive disorder", mainly manifested as stagnation of liver qi, transformation of liver qi into fire, liver depression and spleen deficiency, deficiency of both the heart and spleen, and disharmony between the heart and kidney. Traditional Chinese medicine has the advantages of small toxic and side effects, multi-target synergy, and significant antidepressant effects, and is widely used in the improvement and treatment of depression. Modern clinical practice and pharmacology indicate that Yueju Pills have significant antidepressant effects. However, the traditional usage of Yueju Pills is to make water-pan pills and directly use the whole medicine as medicine. Its formula components are complex and the core efficacy components are not clear. Therefore, it is particularly important to extract the key quality attributes of Yueju Pills, screen out the formula with clear efficacy components, optimize the preparation process, and obtain a composition with clear efficacy components and superior antidepressant effects.

[0005] In view of this, the present invention is specifically proposed. Summary of the Invention

[0006] The purpose of the present invention is to provide a composition for treating depression and its application. The composition for treating depression of the present invention can regulate the content of monoamine neurotransmitters in the brain tissue, and thus exert antidepressant effects.

[0007] In order to achieve the above object of the present invention, the following technical solutions are specifically adopted:

[0008] The first aspect of the present invention provides a composition for treating depression, and the composition for treating depression comprises the following components in parts by weight:

[0009] Ligustilide 35 - 40 parts, Atractylodin 0.5 - 1.5 parts, and α-Cyperone 0.1 - 1 part.

[0010] Preferably, the composition for treating depression comprises the following components in parts by weight:

[0011] Ligustilide 37 - 39 parts, Atractylodin 0.8 - 1.2 parts, and α-Cyperone 0.2 - 0.5 parts.

[0012] The second aspect of the present invention provides an application of the above composition for treating depression in the preparation of a product for treating depression.

[0013] Preferably, the product is a drug or a health product.

[0014] The third aspect of the present invention provides a drug for treating depression, and the drug for treating depression comprises a therapeutically effective amount of the composition for treating depression.

[0015] Preferably, the drug for treating depression further comprises pharmaceutically acceptable excipients.

[0016] Preferably, the dosage form of the drug for treating depression includes oral liquid, pill, powder, granule, tablet, capsule, and injection.

[0017] A fourth aspect of the present invention provides a health product for treating depression, the health product for treating depression comprising the composition for treating depression.

[0018] Preferably, the health supplement for treating depression also includes food-grade excipients.

[0019] Compared with the prior art, the beneficial effects of the present invention include at least the following:

[0020] This invention established a reserpine mouse depression model to evaluate the antidepressant efficacy of the active ingredients, showing that the active ingredients screened for 5-HT1AR and 5-HTT targets can regulate the content of monoamine neurotransmitters in brain tissue and exert antidepressant effects in vivo. In vivo pharmacodynamic experiments fully confirmed the antidepressant efficacy of the composition of this invention.

[0021] Furthermore, this invention is the first to combine the active ingredients in Yueju Pill that target 5-HT1AR and 5-HTT, creating a new composition of traditional Chinese medicine active ingredients. The antidepressant efficacy of the composition was investigated and compared with that of the water extract and alcohol extract of Yueju Pill. This invention demonstrates that the three active monomers combined in this invention, based on the classic formula Yueju Pill, have a better therapeutic effect than the single monomers administered alone. In other words, this invention clarifies the key active ingredients in the classic formula Yueju Pill that play an antidepressant role and their antidepressant efficacy, and it is expected that these active ingredients can be developed into new drugs for improving and / or treating depression and anxiety. Attached Figure Description

[0022] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the accompanying drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to scale.

[0023] Figure 1 This invention demonstrates the reserpine-induced depression model and the effect of drug intervention on mouse body weight in experimental examples.

[0024] Figure 2 This invention illustrates the effects of a depression model and drug intervention on sucrose preference in mice in experimental examples.

[0025] Figure 3 This invention illustrates the effects of a depression model and drug intervention on the immobility time during forced swimming in experimental examples.

[0026] Figure 4 This illustrates the effects of a depression model and drug intervention on tail immobility time in the experimental examples of this invention.

[0027] Figure 5 The effects of different components on the levels of 5-HT, NE, and DA in the serum of depressed mice in the experimental examples of this invention;

[0028] Figure 6 The effects of different components on the levels of 5-HT, NE, and DA in the brain tissue of depressed mice in the experimental examples of this invention;

[0029] Figure 7 This invention illustrates the effects of different components on Nissl bodies in the hippocampus of depressed mice in experimental examples. Detailed Implementation

[0030] The embodiments of the technical solution of the present invention will be described in detail below with reference to the examples. The following embodiments are only used to illustrate the technical solution of the present invention more clearly, and are therefore only examples, and should not be used to limit the scope of protection of the present invention.

[0031] It should be noted that, unless otherwise stated, the technical or scientific terms used in this application should have the ordinary meaning as understood by one of ordinary skill in the art to which this invention pertains.

[0032] Currently, theories regarding depression mainly focus on the effects on neurons and neuronal brain networks. The protective effect of antidepressants on neurons is also an important indicator for evaluating their activity. Furthermore, in vivo animal models of depression can simulate the core symptoms of human depression and induce changes in behavioral, neurochemical, and neuroendocrine parameters, similar to the neurological dysfunction in patients with depression, which can be improved by the use of antidepressants. In the initial screening using receptor chromatography, the core antidepressant marker components of Yueju Pill were identified as ligustilide, atractylodes, and α-cyperone. Further, using these three components as indicators, orthogonal experiments were employed to optimize the extraction process, and pharmacodynamic studies were conducted on the resulting dry extract and the marker components obtained from the optimal process.

[0033] This invention provides a composition for treating depression, the composition comprising the following components in parts by weight:

[0034] Ligusticin 35-40 parts, atractylodes 0.5-1.5 parts and α-cyperone 0.1-1 parts.

[0035] In some embodiments, the composition for treating depression comprises the following components in parts by weight:

[0036] Ligusticin 37-39 parts, atractylodes 0.8-1.2 parts and α-cyperone 0.2-0.5 parts.

[0037] Another embodiment of the present invention provides the use of the above-described composition for treating depression in the preparation of a product for treating depression.

[0038] In one embodiment, the product is a medicine or health product.

[0039] Another embodiment of the present invention provides a medicament for treating depression, the medicament comprising a therapeutically effective amount of the composition for treating depression.

[0040] In one embodiment, the medicament for treating depression further includes pharmaceutically acceptable excipients.

[0041] In one embodiment, the dosage form of the drug for treating depression includes oral liquid, pills, powder, granules, tablets, capsules, and injections.

[0042] Another embodiment of the present invention provides a health product for treating depression, the health product for treating depression comprising the composition for treating depression.

[0043] In one embodiment, the health supplement for treating depression also includes food-grade excipients.

[0044] The technical solution of the present invention will be further described in detail below through specific embodiments.

[0045] Example 1

[0046] This embodiment is a composition for treating depression, which comprises the following components in parts by weight:

[0047] 35 parts of ligustilide, 0.5 parts of atractylodesin, and 1 part of α-cyperone.

[0048] Example 2

[0049] This embodiment is a composition for treating depression, which comprises the following components in parts by weight:

[0050] 40 parts of ligustilide, 1.5 parts of atractylodes, and 0.1 parts of α-cyperone.

[0051] Example 3

[0052] This embodiment is a composition for treating depression, which comprises the following components in parts by weight:

[0053] 38 parts of ligustilide, 1 part of atractylodes lancea and 0.3 parts of α-cyperone.

[0054] Comparative Example 1

[0055] This comparative example is an aqueous extract of a certain type of *Echigon jujuba*, which was prepared by the following method:

[0056] After crushing the traditional Chinese medicinal materials of Yueju Pills, they were added to 12 times the amount of water and extracted for 1.5 h. The extraction was carried out three times, and the extraction solutions were combined, concentrated, and dried to obtain the aqueous extract.

[0057] Comparative Example 2

[0058] This comparative example is an ethanol extract of Yueju Pills, which was prepared by the following method:

[0059] After crushing the traditional Chinese medicinal materials of Yueju Pills, they were added to 12 times the amount of 70% ethanol solution and extracted for 1.5 h. The extraction was carried out three times, and the extraction solutions were combined, concentrated, and dried to obtain the ethanol extract.

[0060] Experimental Example

[0061] A mouse depression model was constructed by continuous intraperitoneal injection of reserpine for 14 days. Behavioral experiments were used to investigate the improvement effects of the ethanol extract, aqueous extract, and the index components ligustilide, atractylodin, and α - cyperone alone and in combination on the depressive-like behaviors of depressive mice. ELISA kits were used to determine the contents of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the hippocampal tissue and serum of the mice's brains, and to clarify the antidepressant pharmacodynamic effects of the extracts and the index component combinations.

[0062] 1. Animal grouping and administration

[0063] C57BL / 6J mice were randomly grouped (9 mice in each group), including a blank control group (Con), a model group (Reserpine), a fluoxetine group (Fluoxetine), an aqueous extract group, a low-dose ethanol extract group, a medium-dose ethanol extract group, a high-dose ethanol extract group, a ligustilide group, an atractylodin group, an α - cyperone group, and a monomer compound group. Except for the blank control group, the other groups were induced with a depressive model by intraperitoneal injection of reserpine and gavaged for two weeks. Food was withdrawn two hours before gavage, and normal saline or reserpine was intraperitoneally injected one hour after gavage. The administration doses are shown in Table 1, and the administration doses of each composition and the medicinal material extract were calculated according to the amount of crude medicinal materials.

[0064] Table 1 Experimental animal grouping and administration doses

[0065] Serial Number Grouping drug Dosage 1 Normal control group (Con) physiological saline 0.2 mL / 25g 2 Model group (Reserpine) physiological saline 2.84 mg / kg 3 Positive drug group (Fluoxetine) Fluoxetine 12 mg / kg 4 Aqueous extract group Water extract 1.48g / kg 5 Low dose group alcohol extract 0.5g / kg 6 Medium dose group alcohol extract 1g / kg 7 High dose group alcohol extract 2 g / kg 8 Ligustilide group ligustilide 35.6 mg / kg 9 Atractylodes Atractylodes lancea 0.92 mg / kg 10 α-Cyperone group α-Cyperone 0.3 mg / kg 11 Combination therapy (LCA) Ligustrazine, atractylodesin, α-cyperone (38:1:0.3) 36.82 mg / kg

[0066] 2. Behavioral evaluation

[0067] 2.1 Sucrose preference experiment

[0068] The mice were housed individually in cages according to the groups, provided with 1 bottle of 1% sucrose solution and 1 bottle of pure water, and the sucrose consumption of the mice within 6 h was measured to calculate the sucrose preference rate. Sucrose preference rate (%) = sucrose consumption / total liquid consumption × 100%.

[0069] 2.2 Forced Swimming Experiment

[0070] Mice were placed in a transparent cylindrical container (50 cm high and 20 cm in diameter) with a water depth of 35 cm and a water temperature of 23–25 ℃. The mice were forced to swim for 3 minutes, and the immobility time (s) of the mice within 3 minutes was recorded. The immobile state of the mice was defined as the mice passively floating in the water and giving up struggling for more than 3 seconds.

[0071] 2.3 Mouse tail suspension test

[0072] The mouse was secured to the posterior third of its tail with tape and suspended from a support, with its head 15 cm above the table surface, for imaging. A white background was used for the C57BL / 6J mouse. Timing was stopped after 6 minutes, and the mouse remained still for the last 4 minutes.

[0073] 3. Determination of neurotransmitter content in mouse serum and brain tissue

[0074] After behavioral evaluation, whole blood was collected from mice in each group via enucleation. The blood was centrifuged at 5000 rpm for 10 min at 4°C, and the supernatant was transferred to a new centrifuge tube and stored at -80°C. Serum 5-HT, DA, and NE levels were measured using an ELISA kit. The levels of 5-HT, DA, and NE in mouse hippocampal tissue were also measured using an ELISA kit. Tissue samples were homogenized in PBS at a 1:10 ratio at low temperature. The homogenate was centrifuged at 10000 rpm for 10 min at 4°C, and the supernatant was used to determine the content of the test samples.

[0075] 4. Determination of neurotransmitter content in mouse serum and brain tissue

[0076] After blood collection, mice were euthanized by cervical dislocation, and brain tissue was quickly dissected. The hippocampus was isolated and fixed in 4% paraformaldehyde (PFA, pH 7.4) for 24 hours (4°C).

[0077] Dehydration and embedding: Dehydrated using a gradient of ethanol (70%, 80%, 90%, 95%, 100%, 1 hour each), cleared with xylene, then embedded in paraffin (60°C). Serial coronal sections (5 μm thick) were prepared using a paraffin microtome and mounted on poly-L-lysine-coated slides. The slides were then baked at 60°C for 2 hours. Nissl staining was performed as follows:

[0078] ① Dewaxing and hydration: Dewaxing with xylene I and II for 10 minutes each, followed by rehydration with a gradient of ethanol (100%, 95%, 80%, 70%) to distilled water.

[0079] ② Staining: Immerse in 0.1% toluidine blue staining solution (pH 4.0) and stain at room temperature in the dark for 10 minutes.

[0080] ③ Differentiation: After rinsing with running water, differentiate with 70% ethanol for 5 seconds (under a microscope, control until the background is transparent and the Nissl bodies appear dark blue).

[0081] ④ Dehydration and mounting: Dehydrate with gradient ethanol (80%, 95%, 100% for 30 seconds each), clear with xylene for 5 minutes, and mount with neutral resin.

[0082] Subsequently, the CA1, CA3 and dentate gyrus regions of the hippocampus were observed under an optical microscope. The Nissl bodies appeared as dark blue granules, and the cell nuclei were pale blue.

[0083] 5. Experimental Results

[0084] 5.1 Effects of drug intervention on body weight in depressed mice

[0085] Figure 1 The study investigated the changes in body weight in mice during the 4-week modeling and 3-week drug administration period. Compared with the normal group, the body weight of the model group mice showed a slow decreasing trend, indicating that reserpine stimulation may cause gastrointestinal dysfunction and decreased appetite in mice, leading to stunted growth. Compared with the model mice, the weight of the drug-treated mice increased significantly, with the high-dose alcohol extract group showing the most significant effect. Compared with the single-drug and two-drug combination groups, the weight change trend of the three monomers combined with LCA was closest to that of the normal group mice, showing a slow increasing trend, indicating that the drug intervention affected the weight loss of mice and improved the anhedonia to some extent.

[0086] 5.2 Effects of drug intervention on sucrose preference in depressed mice

[0087] The sucrose preference test is the most commonly used evaluation indicator in chronic stress-induced depression models. The decreased sucrose preference observed in animal models is a manifestation of anhedonia, a core symptom of depression. Figure 2 As shown, the sucrose preference rate of mice in the depression model group was significantly lower than that in the normal group, indicating that long-term stress caused loss of pleasure in the model mice, suggesting that the mice exhibited depressive symptoms. Compared with the model group, the sucrose preference rate of mice showed varying degrees of regression after drug administration. Among them, the sucrose preference rate was significantly increased in the medium-dose and high-dose groups of the ethanol extract and the LCA monomer combination group, while the three-drug combination group and the positive control group had similar effects.

[0088] 5.3 Effect of drug intervention on immobility time during forced swimming in depressed mice

[0089] The forced swimming experiment presents an environment where animals struggle desperately to escape but are unable to, creating an inescapable and oppressive atmosphere. After a period of time, the animals exhibit a typical "immobile state," reflecting a state of "behavioral despair." The experiment assesses the degree of despair in model mice by observing their time spent stationary (without any movement other than maintaining their nose above the water), struggling time (vigorous movements of the forepaws), and swimming time (rhythmic up-and-down paddling movements of the forepaws). Figure 3 As shown, compared with the control group, the model mice had a longer immobility time during swimming, i.e., a longer resting time, and a more pronounced state of despair. Four weeks after drug administration, the mice were subjected to a forced swimming test. The results showed that compared with the model group, the immobility time of the mice in the drug administration group was significantly reduced (p<0.05). The ethanol extract group showed a dose-dependent improvement, and the LCA monomer compound group also showed a significant improvement.

[0090] 5.4 Effects of drug intervention on tail suspension immobility time in depressed mice

[0091] The experiment utilized mice that, after being suspended by their tails and attempting to escape but failing, gave up struggling and entered a specific state of depressed immobility. The duration of immobility was recorded to reflect this depressive state, and antidepressants significantly shortened or altered this state. For example... Figure 4 As shown, compared with the normal group, the tail immobility time of mice in the model group was significantly increased (p<0.001), indicating that reserpine-induced depression mice exhibited core depressive symptoms; compared with the model group, the tail immobility time of the drug-treated groups was significantly reduced, indicating that drug intervention could alleviate depressive symptoms and hopelessness in mice. Among the drug-treated groups, the ethanol extract (p<0.001) and LCA (p<0.001) showed significant antidepressant effects.

[0092] 5.5 Changes in serum 5-HT, NE, and DA levels in depressed mice after drug intervention

[0093] In depression research, in addition to measuring the levels of three neurotransmitters—serotonin (5-HT), norepinephrine (NE), and dopamine (DA)—in the hippocampus of mice, measuring these three indicators in serum is also of significant scientific importance. Serum levels of monoamine neurotransmitters reflect the body's overall physiological state. Unlike the concentration of neurotransmitters in local tissues (such as the hippocampus), serum levels are more indicative of the body's overall psychological state and biological responses. Measuring serum levels of 5-HT, NE, and DA can provide an assessment of the systemic effects of antidepressants. Changes in serum neurotransmitter concentrations can be compared with changes in hippocampal tissue, further revealing the mechanisms of action of active ingredients. For example, antidepressants may alleviate depressive symptoms by regulating the levels of these neurotransmitters in serum, thereby affecting neurotransmission mechanisms in the central nervous system.

[0094] like Figure 5 As shown, compared with the normal group, the serum levels of DA, 5-HT, and NE in the model group were significantly reduced (p < 0.01); compared with the model mice, the serum levels of DA, 5-HT, and NE in the treatment group were significantly increased, with the high-dose effect being significant in the alcohol extract group; among the single-drug combination and single-drug groups, the combined LCA group had the strongest upregulation of monoamine neurotransmitters, indicating that the three-drug combination group and the alcohol extract group had the best antidepressant effect compared with other treatment groups.

[0095] 5.6 Effects of drug intervention on the levels of 5-HT, NE, and DA in the hippocampus of mice

[0096] like Figure 6 As shown, compared with the normal group, the levels of DA, 5-HT, and NE in the hippocampus and cortex of mice in the model group were significantly reduced (p < 0.01). Monoamine neurotransmitters play a positive role in the transmission of electrochemical signals in brain neurons, neuronal cell connections, and regeneration, jointly regulating processes such as memory, emotion regulation, and cognition. Therefore, changes in the levels of DA, 5-HT, and NE in the brain indicate that chronic, unpredictable, mild stimulation can successfully induce a mouse model of depression. Compared with the model mice, the levels of DA, 5-HT, and NE in the hippocampus and cortex of mice in the treatment group were significantly increased. Among the extract groups, the high dose of the ethanol extract showed the most significant effect. Among the single-drug combination and single-drug groups, the combined LCA group showed the strongest upregulation of monoamine neurotransmitters, indicating that the three-drug combination group had the best antidepressant effect compared with other treatment groups.

[0097] 5.7 Effects of drug intervention on the histopathology of the hippocampus in mice

[0098] To further investigate the effects of Ziren tablets raw material on the pathological morphology of mouse hippocampal tissue and neurons, Nissl staining was performed on hippocampal tissue sections. Nissl staining is used to observe the distribution and number of Nissl bodies within neurons, reflecting the functional state of neurons. Figure 7 As shown, compared with the normal group, the depression model group showed a significant reduction in Nissl bodies in the hippocampus, a decrease in neuronal volume, and a sparse distribution of Nissl bodies, indicating impaired neuronal function and potential degenerative changes. In contrast, compared with the model group, the positive control group and the LCA combination group showed a significant increase in the number of Nissl bodies after drug treatment, with more uniform distribution and neuronal volume approaching normal levels, indicating that the drugs can promote neuronal repair and restore neuronal function, suggesting that the drugs may improve depression-related neurological damage through neuroprotection. The combined active ingredient group showed a significantly greater effect than the single active ingredient group, indicating that the combined active ingredients can exert antidepressant effects through multiple pathways.

[0099] Figures 1-7In the study, Control group; Reserpine group; Fluoxetine group; Water extract group; 70% ethanol extract low group; 70% ethanol extract middle group; 70% ethanol extract high group; Ligustilide group; Cyberone group; Atractylodin group; LCA group: Ligustilide + α-cyperone + atractylodin group; ###P<0.001 vs. Con; , , .

[0100] In summary, a mouse model of depression was established by continuous intraperitoneal injection of reserpine for 14 days. The effects of the alcohol extract, water extract, and the indicative components ligustilide, atractylodesin, and α-cyperone, used alone and in combination, on the improvement of depressive-like behavior in depressed mice were investigated from three aspects: behavioral, neuroprotective, and monoaminergic. The experimental results showed that the combination of active ingredients could reduce the immobility time in the forced swimming and tail suspension tests of depressed mice, significantly improve depressive-like behavior, and exert neuroprotective and antidepressant effects by regulating the content of monoamine neurotransmitters 5-HT, DA, and NE in mouse brain tissue.

[0101] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be covered within the scope of the claims and specification of the present invention.

Claims

1. A composition for treating depression, characterized by comprising, The composition for treating depression consists of the following components by weight: 35-40 parts of ligustilide, 0.5-1.5 parts of atractylenolide and 0.1-1 part of α-cyperone.

2. The composition for treating depression according to claim 1, wherein The composition for treating depression consists of the following components by weight: 37-39 parts of ligustilide, 0.8-1.2 parts of atractylenolide and 0.2-0.5 part of α-cyperone.

3. Use of the composition for treating depression according to claim 1 or 2 in the preparation of a product for treating depression.

4. Use according to claim 3, characterized in that, The product is a medicine.

5. A medicament for treating depression, characterized by comprising a compound of the formula (I) as an active ingredient. The medicine for treating depression comprises a therapeutically effective amount of the composition for treating depression according to claim 1 or 2.

6. The medicament for treating depression according to claim 5, wherein The medicine for treating depression further comprises a pharmaceutically acceptable excipient.

7. The medicament for treating depression according to claim 5, wherein The dosage form of the medicine for treating depression comprises oral liquid, pill, powder, granule, tablet, capsule and injection.

Images